Depomed to Present at the UBS Global Life Sciences Conference and the Fifth Annual JMP Securities Healthcare Conference

/ Source: GlobeNewswire

MENLO PARK, Calif., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the UBS Global Life Sciences Conference on Tuesday, September 21, 2010 at 9:30 am EDT, and at the Fifth Annual JMP Securities Healthcare Conference on Tuesday, September 28, 2010 at 2:00 pm EDT, both in New York City.

The company will be webcasting its presentation and interested parties can access the live or archived presentation for up to 90 days on the company's website at

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with one product candidate through Phase 3 clinical development, another in Phase 3 clinical development, two approved products on the market and other product candidates in its early stage pipeline. Product candidate DM-1796 has completed Phase 3 clinical development and has been licensed to Abbott Products Inc. A New Drug Application for DM-1796 was accepted by the FDA in the second quarter of 2010. Product candidate Serada® is in Phase 3 clinical development for menopausal hot flashes. GLUMETZA® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended, controlled release of medications to the upper gastrointestinal tract. Benefits of Acuform-enhanced pharmaceuticals include the convenience of once-daily administration, improved treatment tolerability and enhanced compliance and efficacy. Additional information about Depomed may be found on its website,

The Depomed, Inc. logo is available at

CONTACT: Depomed, Inc. Sheilah Serradell 650-462-5900